Scolaris Content Display Scolaris Content Display

Información sobre normas sociales en cuanto al consumo indebido de alcohol en estudiantes universitarios

Appendices

Appendix 1. Ovid MEDLINE search strategy

Phase 1:
1. RANDOMIZED CONTROLLED TRIAL.pt.
2. CONTROLLED CLINICAL TRIAL.pt.
3. RANDOMIZED CONTROLLED TRIALS.sh.
4. RANDOM ALLOCATION. sh.
5. DOUBLE BLIND METHOD. sh.
6. SINGLE BLIND METHOD. sh.
7. or/1 6
8. ANIMALS. sh. not HUMAN. sh.
9. 7 not 8
Phase 2:
10. CLINICAL TRIAL.pt.
11. exp CLINICAL TRIALS/
12. (clin$ adj25 trial$).ti,ab.
13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
14. PLACEBOS.sh.
15. placebo$.ti,ab.
16. random$.ti,ab.
17. RESEARCH DESIGN. sh.
18. or /10‐ 17
19. 18 not 8
20. 19 not 9
21. 9 or 20
Alcohol, social norms and student terms:
22. Brief intervention$.mp. [mp=title, subject heading word, abstract, instrumentation]
23. Social norms intervention$.mp. [mp=title, subject heading word, abstract, instrumentation]
24. (Social$ adj1 norms$).ti,ab.
25. (norm$ adj1 feedback$).ti,ab.
26. (person$ adj1 feedback$).ti,ab.
27. (individual$ adj1 feedback$).ti,ab.
28. (computer$ adj1 feedback$).ti,ab.
29. (market$ adj1 campaign$).ti,ab.
30. normative$.ti,ab.
31. or/ 22 ‐ 30
32. Alcohol$.mp. [mp=title, subject heading word, abstract, instrumentation]
33. Alcohol intervention$.mp. [mp=title, subject heading word, abstract, instrumentation]
34. (alcohol$ adj1use$).ti,ab.
35. (alcohol$ adj1 abuse$).ti,ab.
36. (alcohol$ adj1 misuse$).ti,ab.
37. (binge$ adj1 drink$).ti,ab.
38. binge drink$.mp. [mp=title, subject heading word, abstract, instrumentation]
39. alcohol use$.mp. [mp=title, subject heading word, abstract, instrumentation]
40. alcohol abuse$.mp. [mp=title, subject heading word, abstract, instrumentation]
41. alcohol misuse$.mp. [mp=title, subject heading word, abstract, instrumentation]
42. (alcohol$ adj1 problems$).ti,ab.
43. or/ 32‐42
44. Student$.mp[mp=title, subject heading word, abstract, instrumentation]
45. (university$ adj1 student$).ti,ab.
46. (college$ adj1 student$).ti,ab.
47. education$.mp[mp=title, subject heading word, abstract, instrumentation]
48. or/ 44‐47
44. 21 and 31 and 43 and 48

Appendix 2. Ovid EMBASE, CINAHL, PsycINFO search strategy

  1. Brief intervention$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  2. Social norms intervention$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  3. (Social$ adj1 norm$).ti,ab.

  4. (norm$ adj1 feedback$).ti,ab.

  5. (person$ adj1 feedback$).ti,ab.

  6. (individual$ adj1 feedback$).ti,ab.

  7. (computer$ adj1 feedback$).ti,ab.

  8. (market$ adj1 campaign$).ti,ab.

  9. normative$.ti,ab.

  10. or/1‐9

  11. Alcohol$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  12. alcohol intervention$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  13. (alcohol$ adj1 use$).ti,ab.

  14. (alcohol$ adj1 abuse$).ti,ab.

  15. (alcohol$ adj1 misuse$).ti,ab.

  16. (binge$ adj1 drink$).ti,ab.

  17. binge drink$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  18. alcohol use$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  19. alcohol abuse$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  20. alcohol misuse$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  21. (alcohol$ adj1 problem$).ti,ab.

  22. or/11‐21

  23. 10 and 22

  24. student$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  25. (university$ adj1 student$).ti,ab.

  26. (college$ adj1 student$).ti,ab.

  27. education$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]

  28. or/24‐27

  29. 23 and 28

Appendix 3. Cochrane Trials Register search strategy

((social NEAR/5 norm*) OR norms OR normative) and (alcohol OR drink*)

Appendix 4. Criteria for judging risk of bias in randomised controlled trials

Item

Judgement

Description

1. Random sequence generation (selection bias)

Low risk

Investigators describe a random component in the sequence generation process such as random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation

High risk

Investigators describe a non‐random component in the sequence generation process such as odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or series of tests; availability of the intervention

Unclear risk

Insufficient information about the sequence generation process to permit judgement of low or high risk

2. Allocation concealment (selection bias)

Low risk

Investigators enrolling participants could not foresee assignment because 1 of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes

High risk

Investigators enrolling participants could possibly foresee assignments because 1 of the following methods was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. envelopes were unsealed or non­opaque or were not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure

Unclear risk

Insufficient information to permit judgement of low or high risk. This is usually the case if the method of concealment is not described or is not described in sufficient detail to allow a definitive judgement

3. Blinding of participants and providers (performance bias)

Low risk

No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding;

blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have been broken

High risk

No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding;

blinding of key study participants and personnel was attempted, but it is likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding

Unclear risk

Information was insufficient to permit judgement of low or high risk

4. Blinding of outcome assessors (detection bias)

Low risk

No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding;

blinding of outcome assessment was ensured, and it is unlikely that the blinding could have been broken

High risk

No blinding of outcome assessment, and outcome measurement is likely to be influenced by lack of blinding;

blinding of outcome assessment, but it is likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding

Unclear risk

Information was insufficient to permit judgement of low or high risk

5. Incomplete outcome data (attrition bias)

for all outcomes except retention in treatment or dropout

Low risk

No missing outcome data

Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias)

Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate

For continuous outcome data, the plausible effect size (difference in means or standardised difference in means) among missing outcomes was not enough to have a clinically relevant impact on observed effect size

Missing data have been imputed using appropriate methods

All randomly assigned participants were reported/analysed in the group to which they were allocated by randomisation irrespective of non‐compliance and co‐interventions (intention‐to‐treat)

High risk

Reason for missing outcome data likely to be related to true outcome, with imbalance in numbers or reasons for missing data across intervention groups

For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was enough to induce clinically relevant bias in intervention effect estimate

For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes was enough to induce clinically relevant bias in observed effect size

‘As‐treated’ analysis was done with substantial departure of the intervention received from that assigned at randomisation

Unclear risk

Information was insufficient to permit judgement of low or high risk (e.g. number randomly assigned not stated, no reasons for missing data provided; number of dropouts not reported for each group)

6. Selective reporting (reporting bias)

Low risk

The study protocol is available, and all of the study’s prespecified (primary and secondary) outcomes that are of interest for this review have been reported in the prespecified way

The study protocol is not available, but it is clear that published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon)

High risk

Not all of the study’s prespecified primary outcomes have been reported

One or more primary outcomes are reported using measurements, analysis methods or subsets of data (e.g. subscales) that were not prespecified

One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect)

One or more outcomes of interest in the review are reported incompletely so that they cannot be entered into a meta‐analysis

The study report fails to include results for a key outcome that would be expected to have been reported for such a study

Unclear risk

Information was insufficient to permit judgement of low or high risk

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
Figuras y tablas -
Figure 2

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
Figuras y tablas -
Figure 3

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.2 Alcohol‐related problems: 4+ months.
Figuras y tablas -
Figure 4

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.2 Alcohol‐related problems: 4+ months.

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.4 Binge drinking: 4+ months.
Figuras y tablas -
Figure 5

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.4 Binge drinking: 4+ months.

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.6 Quantity of drinking: 4+ months.
Figuras y tablas -
Figure 6

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.6 Quantity of drinking: 4+ months.

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.8 Frequency: 4+ months.
Figuras y tablas -
Figure 7

Funnel plot of comparison: 1 Social norms (SN) vs control, outcome: 1.8 Frequency: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 1 Alcohol‐related problems: up to 3 months.
Figuras y tablas -
Analysis 1.1

Comparison 1 Social norms (SN) vs control, Outcome 1 Alcohol‐related problems: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 2 Alcohol‐related problems: 4+ months.
Figuras y tablas -
Analysis 1.2

Comparison 1 Social norms (SN) vs control, Outcome 2 Alcohol‐related problems: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 3 Binge drinking: up to 3 months.
Figuras y tablas -
Analysis 1.3

Comparison 1 Social norms (SN) vs control, Outcome 3 Binge drinking: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 4 Binge drinking: 4+ months.
Figuras y tablas -
Analysis 1.4

Comparison 1 Social norms (SN) vs control, Outcome 4 Binge drinking: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 5 Quantity of drinking: up to 3 months.
Figuras y tablas -
Analysis 1.5

Comparison 1 Social norms (SN) vs control, Outcome 5 Quantity of drinking: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 6 Quantity of drinking: 4+ months.
Figuras y tablas -
Analysis 1.6

Comparison 1 Social norms (SN) vs control, Outcome 6 Quantity of drinking: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 7 Frequency: up to 3 months.
Figuras y tablas -
Analysis 1.7

Comparison 1 Social norms (SN) vs control, Outcome 7 Frequency: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 8 Frequency: 4+ months.
Figuras y tablas -
Analysis 1.8

Comparison 1 Social norms (SN) vs control, Outcome 8 Frequency: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 9 Peak BAC: up to 3 months.
Figuras y tablas -
Analysis 1.9

Comparison 1 Social norms (SN) vs control, Outcome 9 Peak BAC: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 10 Peak BAC: 4+ months.
Figuras y tablas -
Analysis 1.10

Comparison 1 Social norms (SN) vs control, Outcome 10 Peak BAC: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 11 Typical BAC: up to 3 months.
Figuras y tablas -
Analysis 1.11

Comparison 1 Social norms (SN) vs control, Outcome 11 Typical BAC: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 12 Typical BAC: 4+ months.
Figuras y tablas -
Analysis 1.12

Comparison 1 Social norms (SN) vs control, Outcome 12 Typical BAC: 4+ months.

Comparison 1 Social norms (SN) vs control, Outcome 13 Drinking norms: up to 3 months.
Figuras y tablas -
Analysis 1.13

Comparison 1 Social norms (SN) vs control, Outcome 13 Drinking norms: up to 3 months.

Comparison 1 Social norms (SN) vs control, Outcome 14 Drinking norms: 4+ months.
Figuras y tablas -
Analysis 1.14

Comparison 1 Social norms (SN) vs control, Outcome 14 Drinking norms: 4+ months.

Social norms information compared with controls for prevention of alcohol misuse

Patient or population: university or college students

Settings: college or university settings

Intervention: social norms information (personalised feedback or information campaigns); by delivery mode if subgroup differences were noted between different delivery modes (mailed normative feedback; web/computer feedback; individual face‐to‐face feedback; group face‐to‐face feedback)

Comparison: no intervention (assessment only or alcohol information or alternative (non‐normative) intervention)

Follow‐up: 4+ months

Measurement: self‐reported alcohol consumption (questionnaire scale)

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

Number of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Alcohol‐related problems: 4+ monthsweb/computer normative feedback

Mean alcohol problems scale score was 8.91 in the control group, with a standard deviation of 9.17 (the 69‐point RAPI scale was used by Martens 2013)

The SMD from the meta‐analysis (‐0.04) will result in a decrease of 0.37 in the alcohol problems scale score (95% CI 0.18 to 1.00), from an average of 8.91 to 8.54, based on Martens 2013

(SMD ‐0.04, 95% CI ‐0.11 to 0.02)

11,767 (15)

⊕⊕⊝⊝
Low

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up). Borderline substantial heterogeneity (I2 = 51%)

Alcohol‐related problems: 4+ monthsindividual face‐to‐face normative feedback

Mean alcohol problems scale score was 8.91 in the control group, with a standard deviation of 9.17 (the 69‐point RAPI scale was used by Martens 2013)

The SMD from the meta‐analysis (‐0.15) will result in a decrease of 1.28 in the alcohol problems scale score (95% CI 0.37 to 2.20), from an average of 8.91 to 7.63, based on Martens 2013

(SMD ‐0.14, 95% CI ‐0.24 to ‐0.04)

2327 (11)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

Binge drinking: 4+ months (all delivery modes)

43.9% of control group participants were binge drinkers, defined as those who drink above recommended limits for acute risk (> 40 g/> 60 g ethanol on 1 occasion in the preceding 4 weeks for women and men, respectively) in a study by Kypri 2014

The SMD from the meta‐analysis (‐0.06) will result in 2.7% fewer binge drinkers (95% CI 0.9% to 4.8%), from 43.9% to 41.2%, based on Kypri 2014

(SMD ‐0.06, 95% CI ‐0.11 to ‐0.02)

11,292 (16)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

Quantity of drinking: 4+ months (all delivery modes)

Mean number of drinks per week was 13.74 in the control group, with a standard deviation of 10.77, from the DDQ measure in Martens 2013

The SMD from the meta‐analysis (‐0.08) will result in a decrease of 0.9 drinks consumed each week (95% CI 0.4 to 1.3), from an average of 13.7 drinks per week to 12.8 drinks per week, based on Martens 2013

(SMD ‐0.08, 95% CI ‐0.12 to ‐0.04)

21,169 (32)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

Frequency: 4+ monthsweb/computer normative feedback

Mean number of drinking days per week was 2.74 in the control group, with a standard deviation of 1.54, from the DDQ measure in Martens 2013

The SMD from the meta‐analysis (‐0.11) will result in a decrease of 0.17 drinking days per week (95% CI 0.06 to 0.26), from an average of 2.74 drinking days per week to 2.57 drinking days per week, based on Martens 2013

(SMD ‐0.11, 95% CI ‐0.17 to ‐0.04)

9929 (10)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

Frequency: 4+ monthsindividual face‐to‐face normative feedback

Mean number of drinking days per week was 2.74 in the control group, with a standard deviation of 1.54, from the DDQ measure in Martens 2013

The SMD from the meta‐analysis (‐0.21) will result in a decrease of 0.32 drinking days per week (95% CI 0.15 to 0.48), from an average of 2.74 drinking days per week to 2.42 drinking days per week, based on Martens 2013

(SMD ‐0.21, 95% CI ‐0.31 to ‐0.10)

1464 (8)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

Frequency: 4+ monthsgroup face‐to‐face normative feedback

Mean number of drinking days per week was 2.74 in the control group, with a standard deviation of 1.54, from the DDQ measure in Martens 2013

The SMD from the meta‐analysis (‐0.26) will result in a decrease of 0.40 drinking days per week (95% CI 0.03 to 0.83), from an average of 2.74 drinking days per week to 2.34 drinking days per week, based on Martens 2013

(SMD ‐0.26, 95% CI ‐0.54 to 0.02)

449 (5)

⊕⊕⊝⊝
Low

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up). Substantial heterogeneity (I2 = 55%)

Peak BAC: 4+ months (all delivery modes)

Mean peak BAC was 0.144% in the control group, with a standard deviation of 0.111, from Martens 2013

The SMD from the meta‐analysis (‐0.08) will result in a decrease of 0.009 for peak BAC (95% CI 0.000 to 0.019), from an average of 0.144% to 0.135%, based on Martens 2013

(SMD ‐0.08, 95% CI ‐0.17 to 0.00)

7198 (11)

⊕⊕⊝⊝
Low

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up). Borderline substantial heterogeneity (I2 = 50%)

Typical BAC: 4+ monthsindividual face‐to‐face normative feedback

Mean typical BAC was 0.08% in the control group, with a standard deviation of 0.048, from Schaus 2009

The SMD from the meta‐analysis (‐0.08) will result in a decrease of 0.004 for typical BAC (95% CI ‐0.005 to 0.013), from an average of 0.080% to 0.076%, based on Schaus 2009

(SMD ‐0.08, 95% CI ‐0.26 to 0.10)

490 (4)

⊕⊕⊕⊝
Moderate

Limitations in design and implementation, especially blinding and in some studies high risk of attrition bias (loss to follow‐up)

*The basis for the assumed risk is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
BAC: Blood alcohol concentration; CI: Confidence interval; SMD: Standardised mean difference; DDQ: daily drinking questionnaire; RAPI: Rutgers Alcohol Problem Index (frequency of occurrence of 23 problems from "None" (scored 0) to "More than 5 times" (scored 3) to give a range of scores from 0 to 69).

GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

In the columns illustrating comparative risks: for outcomes where the pooled analysis point estimate and confidence interval showed some effect, we have used results (mean scores and standard deviations) from Martens 2013 to illustrate the effect sizes in terms of the measures used in that study. We chose Martens 2013 because the outcome measures they use are well‐known, generally well regarded, and are typical of the measures used in this field of research: they used the Daily Drinking Questionnaire (DDQ) and the Rutgers Alcohol Problem Index (RAPI).

Figuras y tablas -
Comparison 1. Social norms (SN) vs control

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Alcohol‐related problems: up to 3 months Show forest plot

37

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

1.1 Mailed feedback

6

1045

Std. Mean Difference (IV, Random, 95% CI)

0.10 [‐0.02, 0.22]

1.2 Web feedback

21

10166

Std. Mean Difference (IV, Random, 95% CI)

‐0.15 [‐0.26, ‐0.05]

1.3 Individual face‐to‐face

8

1205

Std. Mean Difference (IV, Random, 95% CI)

‐0.14 [‐0.27, ‐0.00]

1.4 Group face‐to‐face

4

382

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.42, 0.10]

2 Alcohol‐related problems: 4+ months Show forest plot

30

Std. Mean Difference (Random, 95% CI)

Subtotals only

2.1 Mailed feedback

1

64

Std. Mean Difference (Random, 95% CI)

‐0.34 [‐0.83, 0.15]

2.2 Web feedback

15

11767

Std. Mean Difference (Random, 95% CI)

‐0.04 [‐0.11, 0.02]

2.3 Individual face‐to‐face

11

2327

Std. Mean Difference (Random, 95% CI)

‐0.14 [‐0.24, ‐0.04]

2.4 Group face‐to‐face

1

126

Std. Mean Difference (Random, 95% CI)

‐0.62 [‐0.97, ‐0.26]

2.5 Marketing campaign

2

4943

Std. Mean Difference (Random, 95% CI)

‐0.03 [‐0.17, 0.10]

3 Binge drinking: up to 3 months Show forest plot

26

10667

Std. Mean Difference (Random, 95% CI)

‐0.17 [‐0.24, ‐0.09]

3.1 Mailed feedback

2

615

Std. Mean Difference (Random, 95% CI)

‐0.07 [‐0.51, 0.36]

3.2 Web feedback

14

8744

Std. Mean Difference (Random, 95% CI)

‐0.15 [‐0.24, ‐0.06]

3.3 Individual face‐to‐face

6

932

Std. Mean Difference (Random, 95% CI)

‐0.21 [‐0.35, ‐0.07]

3.4 Group face‐to‐face

5

376

Std. Mean Difference (Random, 95% CI)

‐0.28 [‐0.48, ‐0.07]

4 Binge drinking: 4+ months Show forest plot

16

11292

Std. Mean Difference (Random, 95% CI)

‐0.06 [‐0.11, ‐0.02]

4.1 Mailed feedback

1

65

Std. Mean Difference (Random, 95% CI)

‐0.17 [‐0.66, 0.32]

4.2 Web feedback

10

10719

Std. Mean Difference (Random, 95% CI)

‐0.07 [‐0.12, ‐0.02]

4.3 Individual face‐to‐face

5

508

Std. Mean Difference (Random, 95% CI)

0.01 [‐0.17, 0.18]

5 Quantity of drinking: up to 3 months Show forest plot

45

14184

Std. Mean Difference (IV, Random, 95% CI)

‐0.14 [‐0.19, ‐0.09]

5.1 Mailed feedback

5

1020

Std. Mean Difference (IV, Random, 95% CI)

‐0.04 [‐0.21, 0.13]

5.2 Web feedback

28

10889

Std. Mean Difference (IV, Random, 95% CI)

‐0.12 [‐0.18, ‐0.07]

5.3 Individual face‐to‐face

8

1309

Std. Mean Difference (IV, Random, 95% CI)

‐0.24 [‐0.38, ‐0.11]

5.4 Group face‐to‐face

5

411

Std. Mean Difference (IV, Random, 95% CI)

‐0.30 [‐0.49, ‐0.10]

5.5 Marketing campaign

1

555

Std. Mean Difference (IV, Random, 95% CI)

‐0.05 [‐0.22, 0.11]

6 Quantity of drinking: 4+ months Show forest plot

32

21169

Std. Mean Difference (Random, 95% CI)

‐0.08 [‐0.12, ‐0.04]

6.1 Mailed feedback

2

533

Std. Mean Difference (Random, 95% CI)

‐0.13 [‐0.32, 0.06]

6.2 Web feedback

18

13319

Std. Mean Difference (Random, 95% CI)

‐0.07 [‐0.12, ‐0.02]

6.3 Individual face‐to‐face

12

2374

Std. Mean Difference (Random, 95% CI)

‐0.15 [‐0.23, ‐0.08]

6.4 Marketing campaign

2

4943

Std. Mean Difference (Random, 95% CI)

‐0.02 [‐0.13, 0.09]

7 Frequency: up to 3 months Show forest plot

19

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

7.1 Mailed feedback

1

521

Std. Mean Difference (IV, Random, 95% CI)

0.12 [‐0.05, 0.29]

7.2 Web feedback

12

6385

Std. Mean Difference (IV, Random, 95% CI)

‐0.17 [‐0.25, ‐0.09]

7.3 Individual face‐to‐face

4

515

Std. Mean Difference (IV, Random, 95% CI)

‐0.45 [‐0.63, ‐0.28]

7.4 Group face‐to‐face

3

264

Std. Mean Difference (IV, Random, 95% CI)

‐0.03 [‐0.27, 0.21]

8 Frequency: 4+ months Show forest plot

25

Std. Mean Difference (Random, 95% CI)

Subtotals only

8.1 Web feedback

10

9929

Std. Mean Difference (Random, 95% CI)

‐0.11 [‐0.17, ‐0.04]

8.2 Individual face‐to‐face

8

1464

Std. Mean Difference (Random, 95% CI)

‐0.21 [‐0.31, ‐0.10]

8.3 Group face‐to‐face

5

449

Std. Mean Difference (Random, 95% CI)

‐0.26 [‐0.54, 0.02]

8.4 Marketing campaign

2

4943

Std. Mean Difference (Random, 95% CI)

‐0.01 [‐0.09, 0.06]

9 Peak BAC: up to 3 months Show forest plot

11

1902

Std. Mean Difference (IV, Random, 95% CI)

‐0.22 [‐0.33, ‐0.11]

9.1 Mailed feedback

1

94

Std. Mean Difference (IV, Random, 95% CI)

‐0.20 [‐0.60, 0.21]

9.2 Web feedback

4

477

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.35, 0.09]

9.3 Individual face‐to‐face

7

1331

Std. Mean Difference (IV, Random, 95% CI)

‐0.26 [‐0.39, ‐0.13]

10 Peak BAC: 4+ months Show forest plot

11

7198

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.17, 0.00]

10.1 Mailed feedback

1

468

Std. Mean Difference (IV, Random, 95% CI)

‐0.13 [‐0.33, 0.08]

10.2 Web feedback

3

355

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.29, 0.13]

10.3 Individual face‐to‐face

7

1432

Std. Mean Difference (IV, Random, 95% CI)

‐0.16 [‐0.26, ‐0.05]

10.4 Marketing campaign

2

4943

Std. Mean Difference (IV, Random, 95% CI)

0.02 [‐0.18, 0.21]

11 Typical BAC: up to 3 months Show forest plot

8

1336

Std. Mean Difference (IV, Random, 95% CI)

‐0.17 [‐0.31, ‐0.03]

11.1 Mailed feedback

3

253

Std. Mean Difference (IV, Random, 95% CI)

‐0.10 [‐0.35, 0.15]

11.2 Web feedback

1

282

Std. Mean Difference (IV, Random, 95% CI)

‐0.25 [‐0.48, ‐0.01]

11.3 Individual face‐to‐face

4

801

Std. Mean Difference (IV, Random, 95% CI)

‐0.14 [‐0.40, 0.12]

12 Typical BAC: 4+ months Show forest plot

4

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

12.1 Individual face‐to‐face

4

490

Std. Mean Difference (IV, Random, 95% CI)

‐0.08 [‐0.26, 0.10]

13 Drinking norms: up to 3 months Show forest plot

14

Std. Mean Difference (IV, Random, 95% CI)

Subtotals only

13.1 Mailed feedback

2

698

Std. Mean Difference (IV, Random, 95% CI)

‐0.21 [‐0.56, 0.14]

13.2 Web feedback

8

1196

Std. Mean Difference (IV, Random, 95% CI)

‐0.51 [‐0.71, ‐0.31]

13.3 Group face‐to‐face

3

297

Std. Mean Difference (IV, Random, 95% CI)

‐0.44 [‐0.84, ‐0.04]

13.4 Individual face‐to‐face

1

244

Std. Mean Difference (IV, Random, 95% CI)

‐1.40 [‐1.68, ‐1.12]

14 Drinking norms: 4+ months Show forest plot

9

Std. Mean Difference (Random, 95% CI)

Subtotals only

14.1 Web feedback

6

2227

Std. Mean Difference (Random, 95% CI)

‐0.34 [‐0.57, ‐0.11]

14.2 Individual face‐to‐face

1

240

Std. Mean Difference (Random, 95% CI)

‐1.19 [‐1.47, ‐0.92]

14.3 Marketing campaign

2

4943

Std. Mean Difference (Random, 95% CI)

‐0.06 [‐0.23, 0.11]

Figuras y tablas -
Comparison 1. Social norms (SN) vs control